Antigen-specific CD8 lytic phenotype induced by sipuleucel-T in hormone-sensitive or castration-resistant prostate cancer and association with overall survival

Emmanuel S. Antonarakis, Eric J. Small, Daniel P. Petrylak, David I. Quinn, Adam S. Kibel, Nancy N. Chang, Erica Dearstyne, Matt Harmon, Dwayne Campogan, Heather Haynes, Tuyen Vu, Nadeem A. Sheikh, Charles G. Drake

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Purpose: Sipuleucel-T is FDA approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) based on the IMPACT trial showing a 4.1-month benefit in median overall survival (OS) for patients receiving sipuleucel-T versus control. Although efficacy of sipuleucel-T is well established, its mechanism remains incompletely understood. Patients and Methods: Patient samples from three sipuleu-cel-T trials were assessed for peripheral cellular immune responses to the immunogen PA2024 and the target antigen prostatic acid phosphatase (PAP). PAP- and PA2024-specific proliferative and cytolytic responses were characterized to delineate sipuleucel-T-induced immune responses. To quantify potential cytotoxic T lymphocyte (CTL) activity, cell-surface CD107a expression on PAP- or PA2024-specific CD8þ T cells was measured in sipuleucel-T-treated patient and healthy volunteer samples. Results: Increased PA2024-specific CD4þ (P ¼ 0.030) and CD8þ (P ¼ 0.052) T-cell proliferation from baseline to week 6 was observed (N ¼ 14) post-sipuleucel-T, with greater magnitude of PA2024-specific responses compared with PAP. PAP- and PA2024-CTL activity (CD107a positivity) significantly increased at weeks 6 and 26 after sipuleucel-T treatment (P < 0.0001; N ¼ 22). At 26 weeks post-sipuleucel-T, OS correlated with the magnitude of PAP (Pearson R, 0.52; P ¼ 0.013) or PA2024 (Pearson R, 0.67; P ¼ 0.0006) CTL activity. Higher PA2024-CTL activity at week 26 was significantly associated with longer OS using tertile analysis (P ¼ 0.0005; N ¼ 22), with PA2024 responses correlating with PAP responses at week 26 (R ¼ 0.90; P ¼ 1.53E08). Conclusions: This study is the first to report PAP-specific CD8þ T-cell responses elicited by sipuleucel-T treatment. Increased and persistent potential PA2024-specific CTL activity correlated with PAP-specific CTL activity and associated with improved OS following sipuleucel-T treatment.

Original languageEnglish (US)
Pages (from-to)4662-4671
Number of pages10
JournalClinical Cancer Research
Issue number19
StatePublished - Oct 1 2018
Externally publishedYes

Bibliographical note

Funding Information:
D. Petrylak is a consultant/advisory board member for and reports receiving commercial research grants from Dendreon. D.I. Quinn is a consultant/advisory board member for Astellas, Bayer, Dendreon, Genzyme, Janssen, and Pfizer. C. Drake is a consultant/advisory board member for Dendreon. No potential conflicts of interest were disclosed by the other authors.

Funding Information:
This study was sponsored by Dendreon Pharmaceuticals LLC, the manufacturer of sipuleucel-T. Medical writing services provided by Swati Ghatpande, PhD, from Nexus Global Group Science, LLC, were funded by Dendreon Pharmaceuticals LLC.

Publisher Copyright:
© 2018 American Association for Cancer Research.


Dive into the research topics of 'Antigen-specific CD8 lytic phenotype induced by sipuleucel-T in hormone-sensitive or castration-resistant prostate cancer and association with overall survival'. Together they form a unique fingerprint.

Cite this